Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2023 Feb;88(2):473.
doi: 10.1016/j.jaad.2022.06.023. Epub 2022 Jun 17.

Response to "Comment on 'Guidelines of care for the management of actinic keratosis'"

Affiliations
Comment

Response to "Comment on 'Guidelines of care for the management of actinic keratosis'"

Daniel B Eisen et al. J Am Acad Dermatol. 2023 Feb.
No abstract available

Keywords: actinic keratosis; actinic keratosis guidelines; actinic keratosis natural history; squamous cell carcinoma.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest Dr Schlesinger serves as an investigator for AbbVie, Aclaris Therapeutics, Inc, Arcutis Premier Research, Arcutis Biotherapeutics, Akros, Allergan, Astellas Pharma US, AOBiome Therapeutics, Bioderma, Biofrontera, BioPharmx, Boehringer Ingelheim, Bristol-Myers Squibb, Cara Therapeutics, Castle BioScience, Celgene, Centocor Ortho Biotech, Inc, ChemoCentryx, Coherus Biosciences, Corrona, Inc, Demira, Dermavant Sciences, DT Pharmacy & DT Collagen, Eli Lilly and Company, Galderma USA, Genentech, Janssen Pharmaceuticals, Kinex, Kiniksa Pharmaceuticals, Ltd, LEO Pharmaceuticals, Merz Aesthetics, Novartis, Pfizer, Regeneron Pharmaceuticals, Sanofi, Sebacia, Inc, Sienna Biopharmaceuticals, SiSaf Ltd, Tetra Derm Group, LLC, and Trevi receiving grants and/or research funding; as a consultant for AbbVie, Aclaris Therapeutics, Inc, Allergan, Inc, Almirall, BioFrontera, Bristol-Meyers Squibb, Castle Biosciences, Eli Lilly and Company, Evolus, Foundation for Research and Education in Dermatology, EPI Health, Galderma USA, LEO Pharmaceuticals, Lilly, MED Learning Group CME Program, Merz Aesthetics, MJH Associates, Nextphase, Novartis, Ortho Dermatologics, Pfizer, Inc, Prolacta Bioscience, Regeneron, SiSaf Ltd, Sun Pharma, Suneva Medical, UCB, Unilever, and Verrica receiving honoraria and/or fees; as a speaker for Aclaris, Almirall, Demira, DUSA, EPI Health, Regeneron, Sanofi Genzyme, Sun Pharma, Suneva Medical, Inc, and Sun Pharmaceutical Industries Ltd receiving honoraria; as an advisory board member for Allergan, Almirall, Amgen, Bioderma, Biofrontera AG, Celgene, Greenway Therapeutix (no compensation received), Remedly, Inc, and Suneva Medical, Inc receiving honoraria and/or stock; and as an independent contractor for SiSaf Ltd receiving grants and/or research funding. Drs Eisen and Green have no conflicts of interest to disclose.

Comment on

MeSH terms